← Back to Clinical Trials
Recruiting NCT06041659

NCT06041659 Functional Magnetic Resonance-Based Observations of Brain Networks in Moyamoya Disease Patients Under Anesthesia

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06041659
Status Recruiting
Phase
Sponsor Beijing Tiantan Hospital
Condition Moyamoya Disease
Study Type OBSERVATIONAL
Enrollment 48 participants
Start Date 2023-10-24
Primary Completion 2025-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 48 participants in total. It began in 2023-10-24 with a primary completion date of 2025-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Moyamoya disease is characterized by progressive stenosis of the genesis of the distal internal carotid arteries bilaterally and progressive generation of compensatory pathological vascular networks at the basis cranii, and these pathological vasculature has poor vascular reactivity. Perioperative circulatory management of patients with smoky vessels to ensure perfusion of brain tissue and integrity of brain network during surgery to minimize postoperative impairment of neurological functions, including motor, sensory, emotional and cognitive functions, is the key point of perioperative circulatory management of moyamoya disease. Functional Magnetic Resonance Imaging (fMRI) has been routinely used in various cerebrovascular diseases to further evaluate cerebrovascular reserve and cerebral network connectivity. The purpose of this study is to observe the changes in cerebral blood flow, cerebral oxygen metabolism, cerebral oxygen metabolism rate, and cerebral network connectivity in adult patients with moyamoya disease in cerebral ischemia-sensitive areas under anesthesia to provide a basis for exploring anesthesia management to improve cognitive function and cerebral network connectivity in these patients.

Eligibility Criteria

Inclusion Criteria: * Patients with moyamoya disease scheduled for direct or indirect intracranial and extracranial revascularization surgery * Age between 18-65 years * Obtain written informed consent. Exclusion Criteria: * Patients with preoperative claustrophobia, sensory or motor aphasia that are unable to understand and cooperate with the examination * Preoperative cranial imaging suggesting cerebral infarction lesion diameter \>15mm * Patients allergic to anesthetic drugs * Metal implants in the body * Undergoing other experimental drug or instrumentation trials

Contact & Investigator

Central Contact

Shu Li

✉ lishu@bjtth.org

📞 8613699223065

Principal Investigator

Shu Li

PRINCIPAL INVESTIGATOR

Beijing Tiantan Hospital

Frequently Asked Questions

Who can join the NCT06041659 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Moyamoya Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06041659 currently recruiting?

Yes, NCT06041659 is actively recruiting participants. Contact the research team at lishu@bjtth.org for enrollment information.

Where is the NCT06041659 trial being conducted?

This trial is being conducted at Beijing, China.

Who is sponsoring the NCT06041659 clinical trial?

NCT06041659 is sponsored by Beijing Tiantan Hospital. The principal investigator is Shu Li at Beijing Tiantan Hospital. The trial plans to enroll 48 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology